August 21st 2020
Howard A. “Skip” Burris, III, MD, FASCO, FACP, discusses the utility of sacituzumab govitecan-hziy in metastatic triple-negative breast cancer.
August 7th 2020
Howard A. “Skip” Burris, III, MD, FASCO, FACP, discusses using biomarkers to determine the benefits of immunotherapy and chemotherapy in triple-negative breast cancer.
May 28th 2015
Howard Burris, III, MD, chief medical officer and executive director of Drug Development at the Sarah Cannon Research Institute discusses the importance of the ASCO annual meeting, taking place May 29 - June 2.
September 5th 2012
Dr. Howard Burris, from the Sarah Cannon Research Institute, Discusses the mTOR Inhibitor Everolimus for HER2-Negative Breast Cancer.
February 23rd 2012
Dr. Howard Burris from Sarah Cannon Research Institute Discusses Recurrence Scores Predicting pCR
February 8th 2012
Dr. Howard Burris, from the Sarah Cannon Research Institute, Discusses the Stratification of Clinical Trials